Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $70,014 | 30 | 94.9% |
| Travel and Lodging | $3,346 | 10 | 4.5% |
| Food and Beverage | $390.60 | 12 | 0.5% |
| Education | $23.99 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme Corporation | $41,915 | 30 | $0 (2019) |
| PFIZER INC. | $29,488 | 17 | $0 (2024) |
| Philips Electronics North America Corporation | $2,203 | 2 | $0 (2023) |
| Astellas Pharma US Inc | $106.19 | 3 | $0 (2018) |
| Teva Pharmaceuticals USA, Inc. | $61.41 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,488 | 1 | PFIZER INC. ($1,488) |
| 2023 | $4,041 | 3 | Philips Electronics North America Corporation ($2,203) |
| 2022 | $3,036 | 3 | PFIZER INC. ($2,975) |
| 2021 | $2,713 | 2 | PFIZER INC. ($2,713) |
| 2020 | $3,850 | 2 | PFIZER INC. ($3,850) |
| 2019 | $20,886 | 19 | Merck Sharp & Dohme Corporation ($15,549) |
| 2018 | $18,157 | 11 | Merck Sharp & Dohme Corporation ($10,677) |
| 2017 | $19,604 | 12 | Merck Sharp & Dohme Corporation ($15,690) |
All Payment Transactions
53 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/28/2024 | PFIZER INC. | XELJANZ (Drug) | Consulting Fee | Cash or cash equivalent | $1,487.50 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/30/2023 | Philips Electronics North America Corporation | (9520) IGT Devices Undivided (Device) | Consulting Fee | Cash or cash equivalent | $2,145.00 | General |
| Category: Medical Device | ||||||
| 10/13/2023 | Philips Electronics North America Corporation | (9124) LM Undivided (Device) | Food and Beverage | Cash or cash equivalent | $58.45 | General |
| Category: Medical Device | ||||||
| 08/14/2023 | PFIZER INC. | XELJANZ (Drug) | Consulting Fee | Cash or cash equivalent | $1,837.50 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/19/2022 | PFIZER INC. | XELJANZ (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/12/2022 | Teva Pharmaceuticals USA, Inc. | — | Food and Beverage | In-kind items and services | $61.41 | General |
| 06/01/2022 | PFIZER INC. | XELJANZ (Drug) | Consulting Fee | Cash or cash equivalent | $1,225.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/10/2021 | PFIZER INC. | XELJANZ (Drug) | Consulting Fee | Cash or cash equivalent | $1,137.50 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/30/2021 | PFIZER INC. | XELJANZ (Drug) | Consulting Fee | Cash or cash equivalent | $1,575.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/16/2020 | PFIZER INC. | XELJANZ (Drug) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/13/2020 | PFIZER INC. | XELJANZ (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/25/2019 | PFIZER INC. | XELJANZ (Drug) | Consulting Fee | Cash or cash equivalent | $2,094.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/23/2019 | PFIZER INC. | XELJANZ (Drug) | Consulting Fee | Cash or cash equivalent | $6.00 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/18/2019 | Merck Sharp & Dohme Corporation | RECARBRIO (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/03/2019 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $4,675.00 | General |
| 07/03/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 06/13/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $756.82 | General |
| 06/13/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $49.57 | General |
| 06/13/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $44.07 | General |
| 06/13/2019 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $33.05 | General |
| 06/12/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $223.52 | General |
| 06/12/2019 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $143.06 | General |
| 03/29/2019 | Merck Sharp & Dohme Corporation | RECARBRIO (Drug) | Consulting Fee | Cash or cash equivalent | $6,825.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/29/2019 | Merck Sharp & Dohme Corporation | RECARBRIO (Drug) | Travel and Lodging | Cash or cash equivalent | $346.24 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/29/2019 | Merck Sharp & Dohme Corporation | RECARBRIO (Drug) | Food and Beverage | Cash or cash equivalent | $13.86 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 17 | 26 | $8,410 | $1,947 |
| 2020 | 1 | 15 | 19 | $5,755 | $1,313 |
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 17 | 26 | $8,410 | $1,947 | 23.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 15 | 19 | $5,755 | $1,313 | 22.8% |
About Dr. Adolf Karchmer, M.D
Dr. Adolf Karchmer, M.D is a Internal Medicine healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508890278.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adolf Karchmer, M.D has received a total of $73,774 in payments from pharmaceutical and medical device companies, with $1,488 received in 2024. These payments were reported across 53 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($70,014).
As a Medicare-enrolled provider, Karchmer has provided services to 32 Medicare beneficiaries, totaling 45 services with total Medicare billing of $3,261. Data is available for 2 years (2020–2021), covering 2 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease
- Location Boston, MA
- Active Since 07/10/2006
- Last Updated 11/09/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1508890278
Products in Payments
- XELJANZ (Drug) $29,488
- MK-7655A (Drug) $16,260
- SIVEXTRO (Drug) $11,156
- RECARBRIO (Drug) $8,424
- (9520) IGT Devices Undivided (Device) $2,145
- (9124) LM Undivided (Device) $58.45
- CRESEMBA (Drug) $42.66
- Cresemba (Drug) $39.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Boston
Michael Mendelsohn, M.d, M.D
Internal Medicine — Payments: $4.6M
David Schenkein, Md, MD
Internal Medicine — Payments: $4.0M
Dr. John Fallon, M.d, M.D
Internal Medicine — Payments: $2.5M
Dr. David Scadden, Md, MD
Internal Medicine — Payments: $2.2M
Dr. James Januzzi, Md, MD
Internal Medicine — Payments: $1.8M
Dr. Marilyn Pike, Md Phd, MD PHD
Internal Medicine — Payments: $1.5M